RESEARCH & INNOVATION SHOWCASE Alan Morgan, Jeff Barclay, Bob Burgoyne (Physiology) Graeme Sills, Tony Marson (Pharmacology/Walton Centre Neurology) Epilepsy.

Slides:

Advertisements

Similar presentations

1 Increasing Biotech Involvement in Global Health Innovation Oxford Conference on Innovation and Technology Transfer for Global Health September 11, 2007.

Advertisements

The Drug Discovery Process

David A Collier Professor of Neuropsychiatric Genetics Institute of Psychiatry Copy Number Variation in neurodevelopmental disorders:

Test-tube or keyboard? Computation in the life sciences.

Michel Goldman, Executive Director Innovative Medicines Initiative (IMI)

Optimization of Preclinical Animal Models Steven Perrin, PhD CEO, CSO ALS Therapy Development Institute.

1 Pharmaceutical Challenges for the Semantic Web.

Influencing Change in Research, Treatment Protocols, and New Drug Development.

Problem statement and opportunity Headwinds: Increasingly difficult to develop therapies with an increased probability of success to differentiate from.

Doug Brutlag 2011 Genomics, Bioinformatics & Medicine Drug Development

ICARE Member Reports ETP seeks to improve incentives and encourage commercial investment in new therapies. (Treatments reach patients only by commercial.

Role of clinical genetics in medicine. Who provides this service Varies depending on structure and funding of service but is in reality provided by many.

Group 6 GERMS, DRUGS and GENES: Revealing mechanisms of gene expression using antibiotics Alejandro Calderon-Urrea Nancy Connell Nigel Crawford Mamta Rawat.

Group 6 GERMS, DRUGS and GENES: Revealing mechanisms of gene expression using antibiotics Alejandro Calderon-Urrea Nancy Connell Nigel Crawford Mamta Rawat.

The South African Malaria Initiative A Case Study E Jane Morris Bridging the Gap in Global Health Innovation - from Needs to.

'Neuroinflammation, excitotoxic and neurodevelopmental disease induce specific forms of Neuronal plasticity: Towards novel platforms for pharmacological.

Chapter 10 Molecular Diagnosis. Keypoints Identification of the gene for a disorder permits diagnostic testing by direct mutation analysis. Some genetic.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke U.S. DEPARTMENT OF HEALTH.

Chapter 13. The Impact of Genomics on Antimicrobial Drug Discovery and Toxicology CBBL - Young-sik Sohn-

1 Discovering new drugs in Africa Defeating Malaria Together Kelly Chibale PhD FRSSAf University of Cape Town.

Trends Biotech 19: 288,2001 GENOMICS FUNCTIONAL GENOMCS PROTEOMICS DRUG DISCOVERY.

Instrumenting the Healthcare Enterprise for Discovery Opening Remarks James Mongan, MD President and CEO Partners HealthCare April 11, 2008.

More than 90% compounds entering clinical trials fail to demonstrate safety and efficacy in human, despite evidence of safety and effectiveness in pre-

Intellectual Property Rights and Pharmaceutical Industry

Limitation of animal models in drug discovery and development Candice Tahimic, Ph.D. Hence, there is a need to use human cells to test the efficacy of.

1 Image-Based Biomedical Big Data Analytics Jens Rittscher Department of Engineering Science, Nuffield Department of Medicine, University of Oxford.

Holy Family Catholic High School 17th April 2007 Developing medicines + Immunity UNIT 11.4 Controlling infectious disease Form 10 A4.

Small change, big difference: the discovery of drug candidate for anti- Schistosomiasis japonicumjaponicum Shandong University, P.R.China Dequn Sun

Dr. Horst Hemmerle Eli Lilly & Company Director Lead Generation Technologies: Responsible for: Compound Collection Enrichment Strategy Screening Strategies.

UCB Inspired by patients. Driven by science.

Recent Advances in Genomic Science Julian Sampson Institute of Medical Genetics, Cardiff.

A model collaboration using the Pool Susanne Hollinger, Ph.D., J.D. Chief Intellectual Property Officer Emory University.

26th April 2016, BioTrinity - London

Wellcome Trust / Glaxo Smith Kline Translational Medicine Training Programme at Imperial College Dr Waljit Dhillo.

VARIOUS APPROACHES TO DRUG DISCOVERY

RESEARCH & INNOVATION SHOWCASE Dr Lauren Walker MRC Clinical Training Fellow supported by the North West England MRC Fellowship Scheme in Clinical Pharmacology.

Targeting APC loss in Colorectal Cancer

Changing the trajectory of drug R&D

NISCHR Academic Health Science Collaboration Launch

Developing chemically modified, non-anticoagulant heparin derivatives as galectin-3-targeted novel anti-cancer/anti-metastasis drugs Professor Lu-Gang.

Nuclear magnetic resonance NMR spectroscopy is a key analytical technique for structure elucidation of a wide range of materials from small molecules to.

Brain Extracellular Matrix in Health and Disease

Biotechnology Objectives: At the end of this lecture we will be able to identify and describe the uses of biotechnology in society.

FACILITATING DRUG DEVELOPMENT FOR TUBEROUS SCLEROSIS COMPLEX

Working Groups (thematic description)

RESEARCH & INNOVATION SHOWCASE Dr Marie M Phelan

An Introduction to Medicinal Chemistry 3/e

Objectives: Understand the nature of antimicrobial chemical compounds that make them useful. Understand the major modes of action by which antimicrobial.

Figure 2 Cumulative proportion of patients experiencing a seizure recurrence after randomization, comparing immediate vs deferred treatment Cumulative.

New Targets, New Modalities, New Challenges – The Inconvenient Path of Human Genetics in Drug Discovery Enabling Precision Medicine: The Role of Genetics.

New Antiepileptic Drugs

New Antiepileptic Drugs

Accelerating drug discovery: Open source cancer cell biology?

Branko Stefanovic Biomedical Sciences

Lixia Yao, James A. Evans, Andrey Rzhetsky Trends in Biotechnology

Name of the disorder.

Association of the genetic polymorphisms in pre-microRNAs with risk of childhood epilepsy in a Chinese population Yang Li, Jinqiu Wang, Chunming Jiang,

Why study Brain tumour Biology???

E.C. Böttger Clinical Microbiology and Infection

Figure 3 Potential interplay between physiological

Pluripotent Stem Cells and Disease Modeling

Consortium: National networks in 16 European countries.

Consortium: National networks in 16 European countries.

10th Anniversary Celebration

Volume 21, Issue 9, Pages (September 2014)

STRATEGIC ACTION IN HEALTH (AES)

Forward and reverse genetic approaches in Drosophila.

The Drosophila pipeline for modeling human disease.

Considerations for Successful Biopharmaceutical Product Development: Discovery to Proof of Concept -A Panel Discussion Stanley C. McDermott, PharmD, MS,

Acute and Chronic Seizures in Patients Older Than 60 Years

Presentation transcript:

RESEARCH & INNOVATION SHOWCASE Alan Morgan, Jeff Barclay, Bob Burgoyne (Physiology) Graeme Sills, Tony Marson (Pharmacology/Walton Centre Neurology) Epilepsy affects 1% of the population One third of patients are resistant to current antiepileptic drugs Existing AEDs act on a narrow range of targets Existing AEDs inhibit seizures, not the underlying disease process New drug discovery models needed based on epilepsy genetics Our approach: use genetic data from patients to develop model organisms as novel drug screening platforms Poster T12

RESEARCH & INNOVATION SHOWCASE Alan Morgan, Jeff Barclay, Bob Burgoyne (Physiology) Graeme Sills, Tony Marson (Pharmacology/Walton Centre Neurology) Find epilepsy mutations Validate In rodents Screen compounds Mutate worm orthologue Marson Sills Human GABRB3 = worm unc-49 A B C D E F Morgan Barclay Burgoyne Sills Poster T12

RESEARCH & INNOVATION SHOWCASE Alan Morgan, Jeff Barclay, Bob Burgoyne (Physiology) Graeme Sills, Tony Marson (Pharmacology/Walton Centre Neurology) We can provide: Novel in vivo drug discovery platform based on emerging clinical genetics Chemical genetic approach to reveal drug molecular targets and MOA Applicability to other neurological disorders (eg, neurodegeneration - poster) We are seeking: Industrial partners interested in target-based phenotypic drug screening Poster T12